Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues.
Recent guidelines for the prevention of opportunistic infections have addressed a variety of issues germane to recipients of hematopoietic stem cell transplant. However, there are several issues regarding postexposure prophylaxis against varicella-zoster virus that remain unresolved. We address these questions and offer several consensus recommendations.
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
David M
DM
Weinstock
Michael
M
Boeckh
Farid
F
Boulad
Janet A
JA
Eagan
Victoria J
VJ
Fraser
David K
DK
Henderson
Trish M
TM
Perl
Deborah
D
Yokoe
Kent A
KA
Sepkowitz
D000212:Acyclovir / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006566:Herpesviridae Infections / Q000517:prevention & control* / Q000628:therapy / Q000635:transmission; D014645:Herpesvirus 3, Human; D006801:Humans; D007106:Immune Sera; D007116:Immunization, Passive; D016867:Immunocompromised Host; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D009894:Opportunistic Infections / Q000517:prevention & control* / Q000628:therapy / Q000635:transmission; D017410:Practice Guidelines as Topic; D055502:Secondary Prevention
D000998:Antiviral Agents; D007106:Immune Sera; C030799:varicella-zoster immune globulin; D000212:Acyclovir